Otezla success in ESTEEM 1 trial for Psoriasis - Celgene

Celgene Corporation released new research findings on Otezla (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.

ESTEEM 1 demonstrated a stable mean PASI improvement of 81 to 88 percent between weeks 32 and 52 for those patients who were treated for 52 weeks with Otezla 30 mg BID and who achieved a PASI-75 score at week 32 (n=77). These data are consistent with the mean PASI-75 improvement observed between weeks 16 and 32. In the same group of patients, Otezla 30 mg BID continued to demonstrate improvements in difficult-to-treat areas affected by Plaque Psoriasis. Among patients who had Nail Psoriasis at baseline (n=46), the majority showed meaningful improvement in their nails. A mean percent decrease from baseline in the Nail Psoriasis Severity Index (NAPSI) of 60.2 percent was observed at week 52. Of those patients who had Scalp Psoriasis defined as moderate or greater at baseline (n=49), the majority continued to demonstrate meaningful improvement in their Scalp Psoriasis with 72.9 percent having reduction of their scalp symptoms to clear or almost clear (ScPGA 0 or 1) at week 52.